Integrated Quantitative Investments LLC Purchases Shares of 50,074 Hims & Hers Health, Inc. (NYSE:HIMS)

Integrated Quantitative Investments LLC bought a new position in shares of Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) during the 4th quarter, according to its most recent disclosure with the SEC. The fund bought 50,074 shares of the company's stock, valued at approximately $1,211,000.

A number of other institutional investors have also recently made changes to their positions in the stock. Rockefeller Capital Management L.P. lifted its holdings in Hims & Hers Health by 5.8% in the third quarter. Rockefeller Capital Management L.P. now owns 33,775 shares of the company's stock valued at $622,000 after buying an additional 1,864 shares during the period. HighTower Advisors LLC bought a new stake in shares of Hims & Hers Health during the 3rd quarter valued at about $207,000. Quarry LP boosted its position in shares of Hims & Hers Health by 91.0% during the 3rd quarter. Quarry LP now owns 6,113 shares of the company's stock valued at $113,000 after purchasing an additional 2,913 shares in the last quarter. State Street Corp grew its stake in Hims & Hers Health by 4.7% during the third quarter. State Street Corp now owns 4,626,543 shares of the company's stock worth $85,221,000 after purchasing an additional 206,078 shares during the period. Finally, Wellington Management Group LLP increased its holdings in Hims & Hers Health by 34.5% in the third quarter. Wellington Management Group LLP now owns 3,444,414 shares of the company's stock worth $63,446,000 after purchasing an additional 883,230 shares in the last quarter. Institutional investors own 63.52% of the company's stock.

Insiders Place Their Bets

In related news, insider Michael Chi sold 7,259 shares of the stock in a transaction dated Friday, January 10th. The stock was sold at an average price of $24.07, for a total transaction of $174,724.13. Following the sale, the insider now owns 193,601 shares of the company's stock, valued at approximately $4,659,976.07. This represents a 3.61 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Soleil Boughton sold 54,153 shares of the firm's stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $29.90, for a total value of $1,619,174.70. Following the completion of the transaction, the insider now owns 165,650 shares of the company's stock, valued at approximately $4,952,935. This represents a 24.64 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 809,806 shares of company stock worth $30,923,658 over the last quarter. 17.71% of the stock is currently owned by company insiders.

Remove Ads

Hims & Hers Health Stock Up 0.1 %

HIMS stock traded up $0.03 during midday trading on Wednesday, hitting $26.13. The company's stock had a trading volume of 10,142,603 shares, compared to its average volume of 14,855,460. Hims & Hers Health, Inc. has a 1 year low of $11.20 and a 1 year high of $72.98. The stock has a market cap of $5.80 billion, a price-to-earnings ratio of 59.86 and a beta of 1.65. The stock's 50-day moving average price is $39.53 and its 200 day moving average price is $30.15.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last posted its quarterly earnings data on Monday, February 24th. The company reported $0.11 EPS for the quarter, beating the consensus estimate of $0.09 by $0.02. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. The business had revenue of $481.14 million for the quarter, compared to the consensus estimate of $494.56 million. As a group, equities analysts forecast that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current fiscal year.

Analyst Ratings Changes

HIMS has been the subject of several recent analyst reports. Truist Financial raised their price objective on shares of Hims & Hers Health from $24.00 to $39.00 and gave the stock a "hold" rating in a research report on Wednesday, February 26th. Bank of America lifted their price target on shares of Hims & Hers Health from $21.00 to $22.00 and gave the company an "underperform" rating in a research note on Tuesday, March 18th. Needham & Company LLC increased their price objective on shares of Hims & Hers Health from $31.00 to $61.00 and gave the stock a "buy" rating in a research report on Tuesday, February 25th. Citigroup restated a "sell" rating on shares of Hims & Hers Health in a research note on Wednesday, April 2nd. Finally, Canaccord Genuity Group upped their price target on Hims & Hers Health from $38.00 to $68.00 and gave the stock a "buy" rating in a research note on Wednesday, February 19th. Two research analysts have rated the stock with a sell rating, seven have given a hold rating and six have issued a buy rating to the company's stock. According to data from MarketBeat.com, the company currently has an average rating of "Hold" and a consensus target price of $37.31.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.